Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Autolus Therapeutics (AUTL) Change in Receivables (2025)

Autolus Therapeutics' Change in Receivables history spans 1 years, with the latest figure at -$8.6 million for Q4 2025.

For Q4 2025, Change in Receivables changed N/A year-over-year to -$8.6 million; the TTM value through Dec 2025 reached $24.2 million, changed N/A, while the annual FY2025 figure was $24.2 million, N/A changed from the prior year.
Change in Receivables reached -$8.6 million in Q4 2025 per AUTL's latest filing, down from $6.0 million in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $14.3 million in Q1 2025 to a low of -$8.6 million in Q4 2025.